Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Fosinopril sodium
Drug ID BADD_D00968
Description Fosinopril is a phosphinic acid-containing ester prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly hydrolyzed to fosinoprilat, its principle active metabolite. Fosinoprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Fosinopril may be used to treat mild to moderate hypertension, as an adjunct in the treatment of congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.
Indications and Usage For treating mild to moderate hypertension, use as an adjunct in treating congestive heart failure, and may be used to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.
Marketing Status approved
ATC Code C09AA09
DrugBank ID DB00492
KEGG ID D00622
MeSH ID D017328
PubChem ID 23666105
TTD Drug ID D0X8KY
NDC Product Code 76282-201; 76282-202; 65862-393; 65977-0004; 65862-472; 65862-471; 62135-042; 62135-043; 71335-1115; 16571-772; 71335-9703; 43547-388; 65862-473; 76282-200; 43547-387; 62135-041; 16571-770; 16571-771
UNII NW2RTH6T2N
Synonyms Fosinopril | Fosenopril | Fosinil | Fositens | Fosinopril Sodium | Sodium, Fosinopril | Fosinopril, (1(S*(R*)),2 alpha,4 beta)-Isomer | Fosinopril, (1(S*(R*)),2 alpha,4 alpha)-(D-Pro)-Isomer | Tenso Stop | Tensocardil | Fozitec | Hiperlex | Monopril | Fosinorm | Newace | Staril | SQ-28,555 | SQ 28,555 | SQ28,555 | SQ-28555 | SQ 28555 | SQ28555 | Dynacil | Fosinopril, (1(S*(S*)),2 alpha,4 beta)-Isomer
Chemical Information
Molecular Formula C30H45NNaO7P
CAS Registry Number 88889-14-9
SMILES CCC(=O)OC(C(C)C)OP(=O)(CCCCC1=CC=CC=C1)CC(=O)N2CC(CC2C(=O)[O-])C3CCCCC3.[Na+]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Leukopenia01.02.02.001--Not Available
Libido decreased21.03.02.005; 19.08.03.001--
Lymphadenopathy01.09.01.002--Not Available
Memory impairment19.20.01.003; 17.03.02.003--
Micturition disorder20.02.02.005--Not Available
Mood altered19.04.02.007--Not Available
Muscle spasms15.05.03.004--
Muscular weakness17.05.03.005; 15.05.06.001--
Musculoskeletal pain15.03.04.007--
Myalgia15.05.02.001--
Myocardial infarction02.02.02.007; 24.04.04.009--
Nausea07.01.07.001--
Neutropenia01.02.03.004--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Oedema peripheral02.05.04.007; 14.05.06.011; 08.01.07.007--
Orthostatic hypotension24.06.03.004; 17.05.01.020--Not Available
Pain08.01.08.004--
Palpitations02.11.04.012--
Pancreatitis07.18.01.001--
Pancytopenia01.03.03.003--Not Available
Paraesthesia17.02.06.005; 23.03.03.094--
Pemphigoid23.03.01.004; 10.04.02.002--Not Available
Pharyngitis22.07.03.004; 11.01.13.003; 07.05.07.004--
Photosensitivity reaction23.03.09.003--
Pollakiuria20.02.02.007--
Pruritus23.03.12.001--
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Renal failure20.01.03.005--Not Available
Renal pain20.02.03.003--Not Available
The 3th Page    First    Pre   3 4 5    Next   Last    Total 5 Pages